Cleveland, Ohio, February 4, 2020 – Thermalin Inc., a privately held biotechnology company with its main laboratories in Cleveland, announces that JDRF, the leading global organization funding type 1 diabetes (T1D) research, presented Thermalin co-founder Michael A. Weiss, M.D., Ph.D., M.B.A. with the prestigious Gerold and Kayla Grodsky Basic Research Scientist Award. This award recognizes a research scientist who has made outstanding pioneering contributions to T1D research. Dr. Weiss is being honored by JDRF for his work on insulin structure and signaling with application to therapeutic insulin analog design. His laboratory has synthesized numerous insulin analogs and, utilizing a range of biophysical and biological tools to explore these analogs’ properties, contributed immensely to the world’s understanding of the structures of insulin, pro-insulin, rapid-acting analogs, and basal analogs and of the mechanics of the hormone’s binding to the insulin receptor.
In 20010, Dr. Weiss founded Thermalin Diabetes, LLC, which sought to design novel ultra-stable pump-based insulin analogs, and he currently serves as Chief Innovation Officer of its successor entity, Thermalin Inc. Dr. Weiss is Chair of the Department of Biochemistry & Molecular Biology and a member of the Center for Diabetes and Metabolic Diseases at the Indiana University School of Medicine; he is also a member of the Department of Chemistry at Indiana University in Bloomington (adjunct) and the Department of Biomedical Engineering at Purdue University (courtesy).
The Grodsky Basic Research Scientist Award is named in honor of Dr. Gerold Grodsky and his late wife, Kayla. JDRF established the award to honor the contributions of Dr. Grodsky’s diabetes research for over four decades at the University of California at San Francisco. Dr. Grodsky is a professor emeritus of Biochemistry and Medicine at UCSF. He has authored more than 225 articles and is a specialist in the synthesis and secretion of insulin.
Thermalin is developing next-generation insulin solutions for people with T1D and T2D. Thermalin’s programs include (1) clinical candidate T-1123—a stabilized insulin analog that is ultra-rapid at both U-100 and U-500, (2) StampPump—a miniaturized glucose management system that will deliver the concentrated, ultra-rapid-acting formulation of T-1123, (3) basal and mix insulins that never need refrigeration, and (4) a glucose-responsive insulin that protects against hypoglycemia by losing potency when glucose levels are below normal. For more information, please visit www.thermalin.com. For background on insulin therapy for diabetes, please visit www.thermalin.com/background.
JDRF is the leading global organization funding T1D research. Their mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.2 billion in research funding since its inception. JDRF is an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. JDRF collaborates with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. JDRF staff and volunteers throughout the United States and six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit www.jdrf.org.